Yovani Marrero-Ponce is the head of Computer-Aided Molecular Discovery and Bioinformatic Research International Netwaork (CAMD-BIR-IN) and full professor of bioorganic, molecular pharmacology, biochemistry, pharmaceutical and medicinal chemistry as well as “rational” drug design. Dr. Marrero-Ponce developed a successful PhD in physico-chemistry in Havana University (2005) and gets your MSc degree in Biochemistry at Medical School of Villa Clara (2003). The main results archived by Dr. Marrero-Ponce are in the area of drug discovery, specifically the development of new computational methods for chem-bio-informatics investigations. In this sense, Marrero-Ponce recently developed several new molecular and macromolecular (proteins and nucleic acids) descriptors for using in the development of QSPR/QSAR, “rational” drug design, characterization of molecular similarity, in silico screening, proteins and nucleic acids classification, macromolecule-drug interactions, folding degree description, and early pharmacokinetics and toxicity prediction. Some of these novel mathematical and physic-chemical theories has been implemented computationally in an in-house software, called TOMOCOMD (acronym of TOpological MOlecular COMputational Design), which is an integrative Chem-bio-informatics platform to support the wet-dry cycle, and combined bioinformatics and chemo-informatics methods to support modern drug discovery. That is to say, Marrero-Ponce research is devoted to the development of novel computational methods, to handling of chemical information, to database mining for hit and lead structure search, to the generation of pharmacophore models for the design of new bio-active compounds and bioinformatic studies. In fact, several novel chemical entities (NCEs) have been discovery by using this biosilico approaches and that could be consider as drug-like compounds and clinically use in the near future in skin cancer (tyrosinase inhibitors), malaria, tripanosomiasis (chagas disease), trichomoniasis as well as again some kind of helmintics. Several of these new lead compound discoveries in the research of Professor Marrero-Ponce have interesting properties and characteristic and some of them are more potent that reference drug used in therapeutic. This has been an extremely hard-work, which is confirmed by the high’s impact publications in international (web of science) journals and in several national and international prizes. In this way, four paper have recently been recognised in the "Top-50 most cited articles" as published in Bioorganic & Medicinal Chemistry 2003-2008, & all Tetrahedron Journals as well as Medical Magazine. Some relevant prizes obtained are: 1) prize of “Real Academia Española de Farmacia” (2009), 2) best young researcher in Cuba (2007), 3) special distinction of the High Education Minister of Cuba for their contribution in computational and mathematical methods in Science (2007), 4) two national award of the academy of science of Cuba (2005 and 2006), 5) golden award for academia results (2001) and most relevant research student’s awards for being the top research student in my class, and 7) others. In addition, some research advising to graduate students (advisor for 12 PhD and 12 Master’s Students) has been guided for this professor. On the other hand, Dr. Marrero-Ponce works closely together with several organic and medicinal chemistry departments in worldwide. This collaboration allows him to test and validate novel chem-bio-informatics methods in real drug design application scenarios and the molecular (drug) discovery of NCEs and drug-like compounds. Professor has rather post-doctoral experiences in eleven international universities/research-centers. In conclusion, the novel approach proposed by Dr. Marrero-Ponce provides the tools for the identification/selection and design/optimisation of compounds with improved drug (and/or lead)-like qualities – often reducing the number of tested compounds, compared with conventional trial-and-error methods. This method permits to reduce the time-to-market and R&D overheads, and increases the rate at which NCEs progress through the pipeline. Such studies, if they are successfully implemented, deliver substantial benefits and act as the bedrock for NCE selection.